Eric H. Wexler
Partner
Areas of Focus
- Private Equity Transactions
- Mergers & Acquisitions
- Technology
- Royalty Monetization
- Corporate & Finance
- Investment Management
- Fund Formation
- Tax
- Project Debt & Equity Finance
- Hedge Funds
- Family Office & Private Wealth
- Real Estate & Infrastructure Funds
- Joint Ventures & Strategic Alliances
- Private Client & Family Office Services
- Fund Manager Transactions
- Private Equity
- Private Capital
- Advises investment funds, family offices and corporate clients in connection with mergers & acquisitions, portfolio investments, reorganizations and fund structuring.
Eric has a diverse corporate practice focusing on mergers & acquisitions (M&A), portfolio investments, reorganizations and fund structuring. In particular, he advises on public and private M&A and divestitures, joint ventures (JV), private equity transactions, fund and corporate restructurings, competitive auctions, asset purchases & sales, transactions involving complex partnership structures, preferred equity investments, initial public offerings (IPOs) and debt financings.
Eric’s strategic advice combines a sophisticated understanding of tax structuring and corporate law matters, often involving significant cross-jurisdictional elements. He works across a wide range of industries, including emerging technologies and life sciences.
Prior to joining Akin, Eric practiced in the New York office of another leading international law firm.
- Represented OpenAI in its multiyear, multibillion-dollar investment from Microsoft. The investment allows OpenAI to continue its development of artificial intelligence (AI).
- Advised small satellites innovator Terran Orbital Corporation in the $1.6-billion business combination with Tailwind Two Acquisition Corp. Terran Orbital is a leading small satellite manufacturer primarily serving the U.S. aerospace & defense industry.
- Represented ProKidney in its $2.64-billion business combination with Social Capital Suvretta Holdings Corp. III. ProKidney is a leading clinical-stage cellular therapeutics company focused on chronic kidney disease.
- Represented Royalty Pharma on its $2.5-billion IPO and listing on the Nasdaq Global Select Market.
- Represented a medical device technology company in a $500-million funding round that valued the business at an $800-million post-money valuation. The funding round included participation by more than 50 investors, including leading family offices in the United States, Latin America and Europe.
EducationJ.D., University of Pennsylvania Law School, magna cum laude, 2011
B.A., Johns Hopkins University, with honors, 2008
J.D., University of Pennsylvania Law School, magna cum laude, 2011
B.A., Johns Hopkins University, with honors, 2008
Bar AdmissionsNew York
New York